Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031

Pfizer Inc. (NYSE:PFE) has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, resolving patent infringement litigation regarding VYNDAMAX (tafamidis). These agreements effectively extend Pfizer's US patent protection for the transthyretin-mediated amyloidosis (ATTR-CM) treatment until June 1, 2031. This is a significant shift from previous projections, which anticipated a sharp revenue decline starting in 2029 due to patent expiration. The extension secures VYNDAMAX's market-leading position, where it currently holds 75% of prescription volume in the ATTR-CM space. Pfizer expects revenues for the drug to remain stable from 2028 through mid-2031, supported by over seven years of clinical data and its status as the only once-daily capsule proven to reduce all-cause mortality and cardiovascular hospitalizations. Aamir Malik, Pfizer's Chief US Commercial Officer, emphasized that the outcome validates the company's innovative science and ensures continued access for patients. In a move to streamline patient care, Pfizer Inc. (NYSE:PFE) also confirmed it discontinued the supply of VYNDAQEL in the US as of late 2025, leaving VYNDAMAX as the primary available option. The decision was made in consultation with clinical experts to prioritize the convenience of the once-daily, single-capsule regimen. This consolidation, paired with the recent legal settlements, reinforces Pfizer's long-term commercial strategy for its cardiovascular portfolio through the next decade.

(Source：Insider Trading)